Reuters logo
Amgen cancer drug meets main goal in late-stage study
August 4, 2014 / 11:56 AM / 3 years ago

Amgen cancer drug meets main goal in late-stage study

Aug 4 (Reuters) - Amgen Inc said its cancer drug significantly improved the length of time that patients lived with a type of blood cancer without the disease worsening.

Amgen’s share rose 4.3 percent to $130.96 in premarket trading on Monday after the company released the interim data from a late-stage study.

The trial was testing the drug, Kyprolis, in combination with two other treatments, against those treatments alone in previously-treated patients with relapsed multiple myeloma. (Reporting by Natalie Grover in Bangalore; Editing by Savio D‘Souza)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below